Fresenius SE & Co. KGaA FSNUY
14.42 USD +0.76 (+5.56%)
Nov 4, 2026, 3:50 PM EST
14.36 Day range 14.57
10.33 52-week range 17.60
- YTD
- +0.63%
- 1 year
- -17.55%
- Market cap
- 32.49B
- EPS (ttm)
- 0.81
- P/E ratio
- 17.80
- YTD return
- +0.63%
- 1-year return
- -17.55%
- Volume
- 11.17K
- Avg volume
- 201.46K
- Open
- 14.40
- Previous close
- 13.66
- Day's range
- 14.36 – 14.57
- 52-week range
- 10.33 – 17.60
- Earnings date
- Nov 4, 2026
3M +0.83 (+6.12%)
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.23.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.23 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.25 | 0.24 | -0.01 | -4.00% |
| May 6, 2026 | Mar 31, 2026 | 0.2535 | 0.24 | -0.01 | -5.33% |
| Feb 25, 2026 | Dec 31, 2025 | 0.269 | 0.28 | +0.01 | +4.09% |
| Nov 5, 2025 | Sep 30, 2025 | 0.208 | 0.23 | +0.02 | +10.58% |
| Aug 6, 2025 | Jun 30, 2025 | 0.2182 | 0.24 | +0.02 | +9.99% |
News
Fresenius SE & Co. KGaA (FSNUY) Q3 2026 Earnings Call Transcript 
Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Still a Buy? 
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now? 
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform 
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock? 
All You Need to Know About Fresenius SE & Co. (FSNUY) Rating Upgrade to Buy 
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock? 
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now? 
Fresenius SE & Co. KGaA (FSNUY) Q2 2026 Earnings Call Transcript 
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
Your note
Sign in to keep a note on FSNUY — it syncs with the Stock Master app.